NASDAQ:CINC CinCor Pharma (CINC) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free CINC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$29.02▼$29.3550-Day Range$28.73▼$29.5652-Week Range$10.53▼$43.15Volume6.35 million shsAverage Volume818,447 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get CinCor Pharma alerts: Email Address Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About CinCor Pharma Stock (NASDAQ:CINC)CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.Read More Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic CINC Stock News HeadlinesMarch 22, 2024 | thestreet.comCinCor Pharma Inc.December 12, 2023 | bbc.comPurdue Pharma to plead guilty in $8bn opioid settlementApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.December 6, 2023 | bizjournals.comImpel Pharmaceuticals hit by another C-suite departureDecember 4, 2023 | marketwatch.comCatalyst Pharma's Finance Chief to Retire, Be Succeeded by Impel's CFONovember 4, 2023 | ca.finance.yahoo.comSmall Pharma Inc. (DMT.V)October 20, 2023 | msn.comAbivax Readies $250 Million U.S. IPO For Drug PipelineJune 9, 2023 | uk.finance.yahoo.comDiabetic Kidney Disease Global Market Report 2023April 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.May 11, 2023 | marketwatch.com8-K: IMPEL PHARMACEUTICALS INCMay 9, 2023 | finance.yahoo.comChronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsightApril 25, 2023 | finanznachrichten.deFinancial Results for the Year Ended 31 December -3-March 16, 2023 | reuters.comNASDAQ Biotechnology IndexMarch 13, 2023 | finance.yahoo.comHOOKIPA Pharma Appoints Terry Coelho to its Board of DirectorsFebruary 21, 2023 | finance.yahoo.comCinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of BaxdrostatFebruary 9, 2023 | msn.comAs demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023January 24, 2023 | marketwatch.comADRs End Higher; AstraZeneca, Barclays Trade ActivelyJanuary 23, 2023 | msn.comBritain's AstraZeneca launches tender offer for CinCor PharmaJanuary 23, 2023 | finance.yahoo.comAstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.January 12, 2023 | msn.comWill 2023 be the year that pharma M&A makes a comeback?January 12, 2023 | seekingalpha.comAstraZeneca Is Acquiring CinCor Pharma: Market Values Interesting CVR At $3.21January 11, 2023 | bizjournals.comAstraZeneca reaches deal to buy CinCor Pharma for up to $1.8 billionJanuary 10, 2023 | finance.yahoo.comAstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor BuyoutJanuary 10, 2023 | marketwatch.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of CinCor Pharma, Inc - CINCJanuary 10, 2023 | finance.yahoo.comAstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor BuyoutJanuary 9, 2023 | msn.comAstraZeneca buying hypertension-focused CinCor for up to $1.8 billionJanuary 9, 2023 | finance.yahoo.comAstraZeneca to Buy CinCor Pharma for Up to $1.8 BillionSee More Headlines Receive CINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CinCor Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CINC CUSIPN/A CIK1868734 Webwww.cincor.com Phone844-531-1834FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.03% Return on Assets-27.21% Debt Debt-to-Equity RatioN/A Current Ratio51.96 Quick Ratio51.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.74) per share Price / Book-16.70Miscellaneous Outstanding Shares43,760,000Free Float36,937,000Market Cap$1.27 billion OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Marc M. P. de Garidel (Age 64)CEO & Director Comp: $776.86kDr. Mason W. Freeman M.D. (Age 71)Chief Medical Officer Comp: $285.56kMs. Catherine Pearce DHSc (Age 46)M.B.A., MBA, Co-Founder & COO Mr. Michael W. Kalb CPA (Age 51)Exec. VP, CFO & Principal Accounting Officer Ms. Ida HatoumSr. VP and Head of People, Talent & CultureHema KeshavaCorp. ControllerMore ExecutivesKey CompetitorsDay One BiopharmaceuticalsNASDAQ:DAWNPacira BioSciencesNASDAQ:PCRXIronwood PharmaceuticalsNASDAQ:IRWDKiniksa PharmaceuticalsNASDAQ:KNSADeciphera PharmaceuticalsNASDAQ:DCPHView All Competitors CINC Stock Analysis - Frequently Asked Questions When did CinCor Pharma IPO? CinCor Pharma (CINC) raised $176 million in an initial public offering (IPO) on the week of November 7th 2022. The company issued 11,000,000 shares at a price of $15.00-$17.00 per share. This page (NASDAQ:CINC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CinCor Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
